Individual Patient Compassionate Use of Fedratinib
| Status: | Available |
|---|---|
| Conditions: | Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 3/6/2019 |
| Contact: | Celgene Medical Information |
| Email: | medinfo@celgene.com |
| Phone: | 1-888-771-0141 |
Compassionate Use of Fedratinib for Patients Who Have Previously Received TG101348, SAR302503 or Fedratinib
This is an expanded access program (EAP) for eligible participants designed to provide access
to Fedratinib.
to Fedratinib.
This program is being offered on a patient by patient basis and will require company,
Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.
Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.
Inclusion Criteria:
Subjects will be considered if they received TG101348, SAR302503 or Fedratinib as a
participant on a clinical trial prior to 31 Jan 2018.
Exclusion Criteria:
Subject is eligible for enrollment in an ongoing clinical trial using Fedratinib or has
been treated with Fedratinib after 31 Jan 2018.
We found this trial at
1
site
